With the continuous development of more and more experimental studies based on protein CD73, many drugs targeting CD73 have been introduced into the clinic, which can be widely used in the field of liver disease in the future, especially providing new treatment options for patients with chronic hepatitis B and chronic hepatitis C, delaying the onset of cirrhosis and liver cancer, and hopefully improving the quality of life of patients with liver diseases. This evidence concerns the gene NT5E and Cirrhosis.